PDS Biotechnology closed at $1.30 on Nov 4, down 7.80%, 18.8% below its 52-week closing high. Volume of 4.6M shares was 0.53× its 20-day average (below normal).
Split-adjusted performance: +24.4% over one month, +22.6% over six months, +39.2% over one year.
Short interest was 3.4M shares at the Oct 15 settlement, up 22.3% from the prior report (8.6% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PDSBPDS Biotechnology | $1.30 | −7.80% | +22.6% | — | — | — | $94.2M | |
| VTVTvTv Therapeutics | $24.03 | +2.04% | −24.1% | — | — | — | $95.0M | Compare |
| MISTMilestone Pharmaceuticals | $0.7725 | +1.74% | −60.8% | — | −5118.8% | — | $96.2M | Compare |
| NTHINeOnc Technologies Holdings | $3.17 | +3.26% | −40.3% | — | — | — | $91.3M | Compare |
| PLYXPolaryx Therapeutics | $1.80 | +4.05% | −52.6% | — | — | — | $89.7M | Compare |
| CATXPerspective Therapeutics | $0.8702 | −1.11% | −77.2% | −72.1% | −33069.1% | — | $99.3M | Compare |
| GNLXGenelux | $1.96 | +2.08% | −31.7% | — | — | — | $88.7M | Compare |
| TNXPTonix Pharmaceuticals Holding | $5.11 | −1.54% | −65.2% | +577.9% | −299.4% | — | $87.6M | Compare |
| RLYBRallybio | $15.90 | +0.25% | +9.2% | −100.0% | — | 3.2 | $85.6M | Compare |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
